This was achieved by packaging the AAV vector with an astrocyte-tropic AAVF capsid and using a GFAP promoter to drive the transgene, with GFAP being elevated in slow-dividing reactive astrocytes associated with the tumors72,106,107 and, to a certain extent, in proliferating tumor cells. This evidence concerns the gene GFAP and neoplasm.